Abstract Body

Background:

We previously demonstrated a higher bone mass among DMPA users on tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) containing ART. However, concerns about metabolic complications remain. We assessed the effect of switching women living with HIV (WLWH) from TDF/ lamivudine/ dolutegravir to Bictergravir /Emtricitabine / TAF (B/F/TAF; Biktarvy®) on body composition over a two-year period in the BONE: STAR study.

Methods:

WLWH on TDF and DMPA-IM were randomized in a 1:1 ratio to either continue on a TDF based ART regimen (HIV+/DMPA+/TDF+) or switch to B/F/TAF (HIV+/DMPA+/TAF+). A third group of WLWH on TDF and using non-hormonal contraception were all offered B/F/TAF (HIV+/DMPA-/TAF+). Dual energy x-ray absorptiometry was used to measure lean mass, total, trunk, and extremity fat at enrollment and every 6 months for 2 years. Multivariable linear regression was used to assess differences in mean percent (%) change in fat and lean mass adjusting for age, and in body mass index.

Results:

A total of 346 WLWH were included in the analysis, with follow-up between December 2019 and August 2023. Median age was 31 years (interquartile range, 27.9 to 34.7 years). Both non-hormonal and DMPA groups who switched to B/F/TAF had significant increases in mean lean mass, total, trunk, and extremity fat post switch, p-value <0.001. There were no significant differences were in body composition parameters between women on B/F/TAF and DMPA or non-hormonal contraception, versus and TDF users, p>0.173. Similarly, no differences were noted between women on B/F/TAF using DMPA versus non-hormonal contraception, p>0.125.

Conclusions:

Significant increases were observed in fat and lean mass in both groups with no differences between DMPA users on TDF and DMPA or non-hormonal contraception switched to B/F/TAF. Longer term follow -up data beyond 2 years are needed to further understand the impact in WLWH of different ART options on fat gain and obesity-related conditions.